Telara Pharma SL

Telara Pharma is redefining glaucoma treatment with Cilastatin (CIL), a neuroprotective compound targeting retinal neurodegeneration. Unlike conventional treatments that lower intraocular pressure (IOP) without stopping disease progression, CIL eye drops reach retina and offer an unprecedented protection for retinal ganglion cells (RGCs). With a strong intellectual property position until 2043, a licensing-driven business model, and a high-value market estimated at $8.8B by 2030.